CD5-positive diffuse large B-Cell lymphoma presenting with protein-losing enteropathy.
1/5 보강
Primary gastrointestinal lymphoma accounts for only 1-4% of all gastrointestinal malignancies, yet the gastrointestinal tract is the most common extranodal site of non-Hodgkin lymphoma, comprising 10-
APA
Moriwaki K, Tatetsu H, et al. (2026). CD5-positive diffuse large B-Cell lymphoma presenting with protein-losing enteropathy.. Journal of clinical and experimental hematopathology : JCEH, 66(1), 45-51. https://doi.org/10.3960/jslrt.25057
MLA
Moriwaki K, et al.. "CD5-positive diffuse large B-Cell lymphoma presenting with protein-losing enteropathy.." Journal of clinical and experimental hematopathology : JCEH, vol. 66, no. 1, 2026, pp. 45-51.
PMID
41922227
Abstract
Primary gastrointestinal lymphoma accounts for only 1-4% of all gastrointestinal malignancies, yet the gastrointestinal tract is the most common extranodal site of non-Hodgkin lymphoma, comprising 10-15% of all non-Hodgkin lymphomas. Among these, diffuse large B-cell lymphoma (DLBCL) and mucosa-associated lymphoid tissue lymphoma frequently affect the stomach and small intestine. Protein-losing enteropathy associated with malignant lymphoma is exceedingly rare, particularly when caused by CD5-positive DLBCL. We report the case of a 60-year-old woman with a four-year history of refractory diarrhea and progressive lower extremity edema, ultimately diagnosed with CD5-positive DLBCL of the small intestine. Diagnostic workup revealed hypoproteinemia with significant protein leakage in the ascending colon and distal small intestine. Double-balloon endoscopy demonstrated shallow, wide ulcers with patchy whitish exudates, and histopathology confirmed a diagnosis of de novo CD5-positive DLBCL. Chemotherapy with rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH-R) led to prompt improvement in serum albumin levels and resolution of the protein-losing enteropathy. Subsequent high-dose chemotherapy with autologous stem cell transplantation has maintained remission. Given the rarity of this presentation and its strong similarity to a previously reported case of CD5-positive DLBCL with protein-losing enteropathy, we propose that this might represent a distinct clinical entity.
MeSH Terms
Humans; Female; Lymphoma, Large B-Cell, Diffuse; Protein-Losing Enteropathies; Middle Aged; CD5 Antigens; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Vincristine; Doxorubicin; Rituximab